Prevention of cutaneous phototoxicity in photodynamic therapy.
Photodynamic therapy using hematoporphyrin derivative (Hpd), or its semipurified form, dihematoporphyrin ether (DHE), in combination with light, has proven effective in the treatment of several types of neoplasms including squamous cell carcinoma. A major disadvantage of this therapy is the long-term retention of these drugs in skin, which may result in cutaneous phototoxicity for weeks after treatment. Singlet oxygen has been identified as the primary cytotoxic product in the reaction of Hpd and light in vitro. This study demonstrates the protective effect in vivo of the singlet oxygen scavengers 1,3 diphenylisobenzofuran and L-tryptophan on the skin of young rats exposed to light after receiving DHE.
McLear
P W
PW
Department of Otolaryngology, Washington University Medical School, St Louis, MO 63110.
Hayden
R E
RE
D000818:Animals; D001572:Benzofurans / Q000627:therapeutic use*; D017323:Dihematoporphyrin Ether; D005260:Female; D006414:Hematoporphyrin Photoradiation / Q000009:adverse effects*; D006415:Hematoporphyrins / Q000627:therapeutic use; D008297:Male; D010778:Photochemotherapy / Q000009:adverse effects*; D010787:Photosensitivity Disorders / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D012867:Skin / Q000187:drug effects; D014364:Tryptophan / Q000627:therapeutic use*
D001572:Benzofurans; D006415:Hematoporphyrins; D010975:Platelet Aggregation Inhibitors; C011238:1,3-diphenylisobenzofuran; D014364:Tryptophan; D017323:Dihematoporphyrin Ether